Then, we added AKT inhibitors and ERK inhibitors (MK2206 and PD98059) to the chambers to test whether the migration and invasion ability of leukemia cells would be blocked, and the results showed that (Figures 5B, C), the migration and invasion ability of leukemia cells in the chambers were attenuated after the addition of MK2206 and PD98059 treatment. Here, MAPK1 is linked to leukemia.